Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Clinical and economic impact of five-year adherence to disease-modifying therapies in a commercially insured multiple sclerosis population.
Role of Subventricular Zone Derived Neural Precursor Cells in the Therapy of Experimental Autoimmune Encephalomyelitis.
Treatment of neuromyelitis optica.
Multiple sclerosis: Response to vitamin D reduced in multiple sclerosis.
Modulation of the Left Prefrontal Cortex with High Frequency Repetitive Transcranial Magnetic Stimulation Facilitates Gait in Multiple Sclerosis.
The impact of detoxifying and repair gene polymorphisms and the levels of serum ROS in the susceptibility to multiple sclerosis.
Caffeine treatment aggravates secondary degeneration after spinal cord injury.
Unusual side effects of interferon Beta-1a in patient with multiple sclerosis.
Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors.
Emerging injectable therapies for multiple sclerosis.
Increased Circulating Th17 Cell Populations and Elevated CSF Osteopontin and IL-17 Concentrations in Patients with Guillain-Barré Syndrome.
Remyelination therapy goes to trial for multiple sclerosis.
A preliminary study of functional imaging upon placebo analgesia in progressive multiple sclerosis.
Spatial Analysis of Multiple Sclerosis Disease in Tehran Metropolitan Zone, Iran, 2001-2012.
CD4(+)HLA-G(+) regulatory T cells: Molecular signature and pathophysiological relevance.
Learning to swim, again: Axon regeneration in fish.
Multiple sclerosis: Vitamin D deficiency leads to excessive B-cell responses in multiple sclerosis.
Impaired Carotid Baroreflex Control of Arterial Blood Pressure in Multiple Sclerosis.
MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients.
Cerebral infarction following subcutaneous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy.
Editorial: Glial Cells: Managers of Neuro-Immunity.
Magnetic resonance frequency shifts during acute MS lesion formation.
Randomized controlled pilot study of customized pamphlets to promote physical activity and symptom self-management in women with multiple sclerosis.
A new CSF1R mutation presenting with an extensive white matter lesion mimicking primary progressive multiple sclerosis.
Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2 Receptor) in Experimental Autoimmune Encephalomyelitis Models of Multiple Sclerosis.
Pages
« first
‹ previous
…
659
660
661
662
663
664
665
666
667
…
next ›
last »